# A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction

> **NCT05891613** · PHASE4 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 32 (actual)

## Conditions studied

- Breast Reduction

## Interventions

- **DRUG:** Bupivacaine Hydrochloride
- **DRUG:** Liposomal Bupivacaine

## Key facts

- **NCT ID:** NCT05891613
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-24
- **Primary completion:** 2025-10-06
- **Final completion:** 2025-10-06
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05891613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05891613, "A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT05891613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*